Nuvectis Pharma, Inc.
NVCT
$9.07
-$0.42-4.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.93M | 7.58M | 7.71M | 7.52M | 7.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.85M | 19.26M | 21.06M | 22.19M | 21.90M |
| Operating Income | -19.85M | -19.26M | -21.06M | -22.19M | -21.90M |
| Income Before Tax | -19.00M | -19.37M | -21.10M | -22.38M | -22.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.00 | -19.37 | -21.10 | -22.38 | -22.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.00M | -19.37M | -21.10M | -22.38M | -22.26M |
| EBIT | -19.85M | -19.26M | -21.06M | -22.19M | -21.90M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.11 | -1.16 | -1.29 | -1.40 | -1.43 |
| Normalized Basic EPS | -0.69 | -0.69 | -0.77 | -0.84 | -0.85 |
| EPS Diluted | -1.11 | -1.16 | -1.29 | -1.40 | -1.43 |
| Normalized Diluted EPS | -0.69 | -0.69 | -0.77 | -0.84 | -0.85 |
| Average Basic Shares Outstanding | 68.45M | 66.89M | 65.77M | 64.04M | 62.21M |
| Average Diluted Shares Outstanding | 68.45M | 66.89M | 65.77M | 64.04M | 62.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
